Combined effects of terazosin and genistein on a metastatic, hormone-independent human prostate cancer cell line

Cancer Letters

Volumn 276, Issue 1, 2009, Pages 14-20

  Chang, Kee Lung ^a   Cheng, Hsiao Ling ^a   Huang, Li Wen ^b   Hsieh, Bau Shan ^a   Hu, Yu Chen ^a   Chih, Tsai Tung ^c   Shyu, Huey Wen ^c   Su, Shu Jem ^c  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c School of Social Medicine   (Taiwan)

Author keywords

Apoptosis; Genistein; Prostate cancer; Terazosin; Vascular endothelial growth factor (VEGF)

Indexed keywords

GENISTEIN; HORMONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROCASPASE 3; PROTEIN BCL X; TERAZOSIN; VASCULOTROPIN 121; VASCULOTROPIN 165;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; FLOW CYTOMETRY; GENISTEIN; HUMANS; IN SITU NICK-END LABELING; MALE; MICROSCOPY, FLUORESCENCE; PRAZOSIN; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 60249088345     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.10.033     Document Type: Article

References (53)

1. Hammond L.A., Brown G., Keedwell R.G., Durham J., and Chandraratna R.A. The prospects of retinoids in the treatment of prostate cancer. Anticancer Drugs 13 (2002) 781-790
2. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics. CA Cancer J. Clin. 57 (2007) 43-66
3. Isaacs J.T. Role of androgens in prostatic cancer. Vitam. Horm. 49 (1994) 433-502
4. Andersson K.E., Lepor H., and Wyllie M.G. Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate 30 (1997) 202-215
5. Kirby R.S., and Pool J.L. Alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia: past, present and future. Br. J. Urol. 80 (1997) 521-532
6. Lepor H., Williford W.O., Barry M.J., Brawer M.K., Dixon C.M., Gormley G., et al. N. Engl. J. Med. 335 (1996) 533-539
7. Kyprianou N., and Jacobs S.C. Induction of apoptosis in the prostate by alpha1-adrenoceptor antagonists: a novel effect of "old" drugs. Curr. Urol. Rep. 1 (2000) 89-96
8. Chon J.K., Borkowski A., Partin A.W., Isaacs J.T., Jacobs S.C., and Kyprianou N. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J. Urol. 161 (1999) 2002-2008
9. Kyprianou N. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. J. Urol. 169 (2003) 1520-1525
10. Kyprianou N., Chon J., and Benning C.M. Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease. Prostate Suppl. 9 (2000) 42-46
11. Tahmatzopoulos A., Rowland R.G., and Kyprianou N. The role of alpha-blockers in the management of prostate cancer. Expert Opin. Pharmacother. 5 (2004) 1279-1285
12. Kyprianou N., and Benning C.M. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res. 60 (2000) 4550-4555
13. Benning C.M., and Kyprianou N. Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action. Cancer Res. 62 (2002) 597-602
14. Alberti C. Apoptosis induction by quinazoline-derived alpha1-blockers in prostate cancer cells: biomolecular implications and clinical relevance. Eur. Rev. Med. Pharmacol. Sci. 11 (2007) 59-64
15. Xu K., Wang X., Ling P.M., Tsao S.W., and Wong Y.C. The alpha1-adrenoceptor antagonist terazosin induces prostate cancer cell death through a p53 and Rb independent pathway. Oncol. Rep. 10 (2003) 1555-1560
16. Keledjian K., and Kyprianou N. Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2. J. Urol. 169 (2003) 1150-1156
17. Garrison J.B., and Kyprianou N. Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway. Cancer Res. 66 (2006) 464-472
18. Keledjian K., Borkowski A., Kim G., Isaacs J.T., Jacobs S.C., and Kyprianou N. Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. Prostate 48 (2001) 71-78
19. Pan S.L., Guh J.H., Huang Y.W., Chern J.W., Chou J.Y., and Teng C.M. Identification of apoptotic and antiangiogenic activities of terazosin in human prostate cancer and endothelial cells. J. Urol. 169 (2003) 724-729
20. Tahmatzopoulos A., and Kyprianou N. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?. Prostate 59 (2004) 91-100
21. Tahmatzopoulos A., Lagrange C.A., Zeng L., Mitchell B.L., Conner W.T., and Kyprianou N. Effect of terazosin on tissue vascularity and apoptosis in transitional cell carcinoma of bladder. Urology 65 (2005) 1019-1023
22. Adlercreutz C.H., Goldin B.R., Gorbach S.L., Hockerstedt K.A., Watanabe S., Hamalainen E.K., et al. Soybean phytoestrogen intake and cancer risk. J. Nutr. 125 Suppl. (1995) S757-S770
23. Adlercreutz H., Honjo H., Higashi A., Fotsis T., Hamalainen E., Hasegawa T., et al. Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet. Am. J. Clin. Nutr. 54 (1991) 1093-1100
24. Messina M., and Barnes S. The role of soy products in reducing risk of cancer. J. Natl. Cancer Inst. 83 (1991) 541-546
25. Knight D.C., and Eden J.A. A review of the clinical effects of phytoestrogens. Obstet. Gynecol. 87 (1996) 897-904
26. Peterson G., and Barnes S. Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation. Prostate 22 (1993) 335-345
27. Davis J.N., Singh B., Bhuiyan M., and Sarkar F.H. Genistein-induced upregulation of p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr. Cancer 32 (1998) 123-131
28. Peterson G., and Barnes S. Genistein inhibition of the growth of human breast cancer cells: independence from estrogen receptors and the multi-drug resistance gene. Biochem. Biophys. Res. Commun. 179 (1991) 661-667
29. Peterson G., and Barnes S. Genistein inhibits both estrogen and growth factor-stimulated proliferation of human breast cancer cells. Cell Growth Differ. 7 (1996) 1345-1351
30. Lian F., Bhuiyan M., Li Y.W., Wall N., Kraut M., and Sarkar F.H. Genistein-induced G2-M arrest, p21WAF1 upregulation, and apoptosis in a non-small-cell lung cancer cell line. Nutr. Cancer 31 (1998) 184-191
31. Su S.J., Yeh T.M., Lei H.Y., and Chow N.H. The potential of soybean foods as a chemoprevention approach for human urinary tract cancer. Clin. Cancer Res. 6 (2000) 230-236
32. Su S., Lai M., Yeh T., and Chow N. Overexpression of HER-2/neu enhances the sensitivity of human bladder cancer cells to urinary isoflavones. Eur. J. Cancer 37 (2001) 1413-1418
33. Su S.J., Chow N.H., Kung M.L., Hung T.C., and Chang K.L. Effects of soy isoflavones on apoptosis induction and G2-M arrest in human hepatoma cells involvement of caspase-3 activation, Bcl-2 and Bcl-XL downregulation, and Cdc2 kinase activity. Nutr. Cancer 45 (2003) 113-123
34. Chang K.L., Kung M.L., Chow N.H., and Su S.J. Genistein arrests hepatoma cells at G2/M phase: involvement of ATM activation and upregulation of p21waf1/cip1 and Wee1. Biochem. Pharmacol. 67 (2004) 717-726
35. Geller J., Sionit L., Partido C., Li L., Tan X., Youngkin T., et al. Genistein inhibits the growth of human-patient BPH and prostate cancer in histoculture. Prostate 34 (1998) 75-79
36. Su S.J., Yeh T.M., Chuang W.J., Ho C.L., Chang K.L., Cheng H.L., et al. The novel targets for anti-angiogenesis of genistein on human cancer cells. Biochem. Pharmacol. 69 (2005) 307-318
37. Bruckheimer E.M., and Kyprianou N. Dihydrotestosterone enhances transforming growth factor-beta-induced apoptosis in hormone-sensitive prostate cancer cells. Endocrinology 142 (2001) 2419-2426
38. Mad'arova J., Lukesova M., Hlobilkova A., Strnad M., Vojtesek B., Lenobel R., et al. Synthetic inhibitors of CDKs induce different responses in androgen sensitive and androgen insensitive prostatic cancer cell lines. Mol. Pathol. 55 (2002) 227-234
39. Tang D.G., and Porter A.T. Target to apoptosis: a hopeful weapon for prostate cancer. Prostate 32 (1997) 284-293
40. Alivizatos G., and Oosterhof G.O. Update of hormonal treatment in cancer of the prostate. Anticancer Drugs 4 (1993) 301-309
41. Lepor H. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group. Urology 45 (1995) 406-413
42. Lowe F.C. Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. Urology 44 (1994) 46-51
43. Rosen R.C., Giuliano F., and Carson C.C. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur. Urol. 47 (2005) 824-837
44. Braganhol E., Zamin L.L., Canedo A.D., Horn F., Tamajusuku A.S., Wink M.R., et al. Antiproliferative effect of quercetin in the human U138MG glioma cell line. Anticancer Drugs 17 (2006) 663-671
45. Purohit A., Hejaz H.A., Walden L., MacCarthy-Morrogh L., Packham G., Potter B.V., et al. The effect of 2-methoxyoestrone-3-O-sulphamate on the growth of breast cancer cells and induced mammary tumours. Int. J. Cancer 85 (2000) 584-589
46. Kessel D., and Luo Y. Cells in cryptophycin-induced cell-cycle arrest are susceptible to apoptosis. Cancer Lett. 151 (2000) 25-29
47. Fujimoto K., Hosotani R., Doi R., Wada M., Lee J.U., Koshiba T., et al. Induction of cell-cycle arrest and apoptosis by a novel retinobenzoic-acid derivative, TAC-101, in human pancreatic-cancer cells. Int. J. Cancer 81 (1999) 637-644
48. Tong W.G., Ding X.Z., Talamonti M.S., Bell R.H., and Adrian T.E. Leukotriene B4 receptor antagonist LY293111 induces S-phase cell cycle arrest and apoptosis in human pancreatic cancer cells. Anticancer Drugs 18 (2007) 535-541
49. Li J.L., Cai Y.C., Liu X.H., and Xian L.J. Norcantharidin inhibits DNA replication and induces apoptosis with the cleavage of initiation protein Cdc6 in HL-60 cells. Anticancer Drugs 17 (2006) 307-314
50. Lowe S.W., Schmitt E.M., Smith S.W., Osborne B.A., and Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362 (1993) 847-849
51. Ferrer F.A., Miller L.J., Lindquist R., Kowalczyk P., Laudone V.P., Albertsen P.C., et al. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 54 (1999) 567-572
52. Jones A., Fujiyama C., Turner K., Fuggle S., Cranston D., Bicknell R., et al. Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer. BJU Int. 85 (2000) 276-280
53. Chen J., De S., Brainard J., and Byzova T.V. Metastatic properties of prostate cancer cells are controlled by VEGF. Cell Commun. Adhes. 11 (2004) 1-11